De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
Embla Medical hf Inkomsten in het verleden
Verleden criteriumcontroles 4/6
De winst van Embla Medical hf is gedaald met een gemiddeld jaarlijks percentage van -0.3%, terwijl de winst van de Medical Equipment -industrie jaarlijks groeide met 10.4%. De inkomsten zijn groeide met een gemiddeld percentage van 4.4% per jaar. Het rendement op het eigen vermogen Embla Medical hf bedraagt 8.1% en de nettomarge bedraagt 7.5%.
Belangrijke informatie
-0.3%
Groei van de winst
-0.7%
Groei van de winst per aandeel
| Medical Equipment Groei van de industrie | -1.7% |
| Inkomstengroei | 4.4% |
| Rendement op eigen vermogen | 8.1% |
| Nettomarge | 7.5% |
| Volgende winstupdate | 22 Oct 2024 |
Recente prestatie-updates uit het verleden
Recent updates
Estimating The Intrinsic Value Of Embla Medical hf. (CPH:EMBLA)
Oct 17
Do Embla Medical hf's (CPH:EMBLA) Earnings Warrant Your Attention?
Oct 02Embla Medical hf.'s (CPH:EMBLA) Share Price Matching Investor Opinion
Aug 22Earnings Beat: Embla Medical hf. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Jul 26Calculating The Fair Value Of Embla Medical hf. (CPH:EMBLA)
Jul 17Market Participants Recognise Embla Medical hf.'s (CPH:EMBLA) Earnings
May 14Embla Medical hf. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Apr 26A Look At The Fair Value Of Embla Medical hf. (CPH:OSSR)
Apr 10Is Össur hf (CPH:OSSR) Using Too Much Debt?
Mar 23Why Investors Shouldn't Be Surprised By Össur hf.'s (CPH:OSSR) P/E
Jan 21Calculating The Intrinsic Value Of Össur hf. (CPH:OSSR)
Jan 03Össur hf (CPH:OSSR) Seems To Use Debt Quite Sensibly
Nov 28Returns On Capital Signal Tricky Times Ahead For Össur hf (CPH:OSSR)
Nov 08A Look At The Fair Value Of Össur hf. (CPH:OSSR)
Sep 23We Think Össur hf (CPH:OSSR) Is Taking Some Risk With Its Debt
Aug 21Össur hf (CPH:OSSR) May Have Issues Allocating Its Capital
Jul 18Össur hf.'s (CPH:OSSR) Intrinsic Value Is Potentially 19% Below Its Share Price
Jun 14Össur hf (CPH:OSSR) Seems To Use Debt Quite Sensibly
May 19Össur hf (CPH:OSSR) Might Be Having Difficulty Using Its Capital Effectively
Mar 14A Look At The Intrinsic Value Of Össur hf. (CPH:OSSR)
Jan 21These 4 Measures Indicate That Össur hf (CPH:OSSR) Is Using Debt Reasonably Well
Dec 22There Are Reasons To Feel Uneasy About Össur hf's (CPH:OSSR) Returns On Capital
Dec 07Are Investors Undervaluing Össur hf. (CPH:OSSR) By 37%?
Sep 21Returns On Capital Signal Tricky Times Ahead For Össur hf (CPH:OSSR)
Sep 02Össur hf (CPH:OSSR) Seems To Use Debt Quite Sensibly
Aug 16Össur hf.'s (CPH:OSSR) Intrinsic Value Is Potentially 42% Above Its Share Price
Jun 16Össur hf (CPH:OSSR) Will Want To Turn Around Its Return Trends
Jun 01Does Össur hf (CPH:OSSR) Have A Healthy Balance Sheet?
May 08Össur hf (CPH:OSSR) Will Be Hoping To Turn Its Returns On Capital Around
Feb 22Analysts Have Made A Financial Statement On Össur hf.'s (CPH:OSSR) Yearly Report
Feb 03Calculating The Fair Value Of Össur hf. (CPH:OSSR)
Nov 25Returns On Capital Signal Tricky Times Ahead For Össur hf (CPH:OSSR)
Oct 17Is Össur hf (CPH:OSSR) A Risky Investment?
Sep 28Calculating The Fair Value Of Össur hf. (CPH:OSSR)
Aug 21Össur hf (CPH:OSSR) Might Be Having Difficulty Using Its Capital Effectively
Jul 11Here's Why Össur hf (CPH:OSSR) Can Manage Its Debt Responsibly
May 28Calculating The Fair Value Of Össur hf. (CPH:OSSR)
May 07There Are Reasons To Feel Uneasy About Össur hf's (CPH:OSSR) Returns On Capital
Mar 25We Think The Compensation For Össur hf.'s (CPH:OSSR) CEO Looks About Right
Mar 02We Think Össur hf (CPH:OSSR) Can Stay On Top Of Its Debt
Feb 22Does The Market Have A Low Tolerance For Össur hf.'s (CPH:OSSR) Mixed Fundamentals?
Feb 09What Kind Of Shareholders Own Össur hf. (CPH:OSSR)?
Jan 26Össur hf (CPH:OSSR) Shareholders Have Enjoyed An Impressive 115% Share Price Gain
Jan 08
Opbrengsten en kosten
Hoe Embla Medical hf geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Jun 24 | 820 | 61 | 371 | 39 |
| 31 Mar 24 | 804 | 57 | 368 | 38 |
| 31 Dec 23 | 786 | 58 | 360 | 38 |
| 30 Sep 23 | 766 | 52 | 353 | 37 |
| 30 Jun 23 | 750 | 45 | 354 | 36 |
| 31 Mar 23 | 730 | 43 | 345 | 34 |
| 31 Dec 22 | 719 | 43 | 339 | 34 |
| 30 Sep 22 | 715 | 47 | 339 | 34 |
| 30 Jun 22 | 719 | 57 | 331 | 33 |
| 31 Mar 22 | 728 | 62 | 331 | 34 |
| 31 Dec 21 | 719 | 64 | 328 | 32 |
| 30 Sep 21 | 701 | 50 | 323 | 32 |
| 30 Jun 21 | 692 | 48 | 318 | 31 |
| 31 Mar 21 | 637 | 11 | 308 | 31 |
| 31 Dec 20 | 630 | 6 | 307 | 31 |
| 30 Sep 20 | 639 | 20 | 303 | 30 |
| 30 Jun 20 | 635 | 19 | 308 | 30 |
| 31 Mar 20 | 680 | 59 | 311 | 31 |
| 31 Dec 19 | 686 | 66 | 308 | 31 |
| 30 Sep 19 | 675 | 83 | 296 | 31 |
| 30 Jun 19 | 652 | 85 | 284 | 31 |
| 31 Mar 19 | 631 | 83 | 274 | 31 |
| 31 Dec 18 | 613 | 80 | 265 | 31 |
| 30 Sep 18 | 599 | 69 | 259 | 31 |
| 30 Jun 18 | 593 | 64 | 254 | 31 |
| 31 Mar 18 | 579 | 58 | 252 | 30 |
| 31 Dec 17 | 569 | 58 | 245 | 29 |
| 30 Sep 17 | 553 | 49 | 246 | 29 |
| 30 Jun 17 | 543 | 51 | 239 | 27 |
| 31 Mar 17 | 538 | 52 | 240 | 25 |
| 31 Dec 16 | 521 | 51 | 233 | 23 |
| 30 Sep 16 | 507 | 49 | 227 | 21 |
| 30 Jun 16 | 495 | 50 | 219 | 20 |
| 31 Mar 16 | 483 | 51 | 209 | 19 |
| 31 Dec 15 | 483 | 51 | 208 | 18 |
| 30 Sep 15 | 488 | 54 | 209 | 18 |
| 30 Jun 15 | 497 | 55 | 213 | 18 |
| 31 Mar 15 | 502 | 57 | 214 | 19 |
| 31 Dec 14 | 509 | 59 | 218 | 19 |
| 30 Sep 14 | 509 | 58 | 217 | 20 |
| 30 Jun 14 | 487 | 55 | 207 | 20 |
| 31 Mar 14 | 460 | 46 | 199 | 21 |
| 31 Dec 13 | 436 | 40 | 189 | 22 |
Kwaliteitswinsten: EMBLA heeft hoge kwaliteitsinkomsten.
Groeiende winstmarge: De huidige netto winstmarges (7.5%) EMBLA } zijn hoger dan vorig jaar (6%).
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: De winst van EMBLA is de afgelopen 5 jaar met 0.3% per jaar gedaald.
Versnelling van de groei: De winstgroei van EMBLA over het afgelopen jaar ( 35.3% ) overtreft het 5-jarig gemiddelde ( -0.3% per jaar).
Winst versus industrie: De winstgroei EMBLA over het afgelopen jaar ( 35.3% ) overtrof de Medical Equipment -sector 17.1%.
Rendement op eigen vermogen
Hoge ROE: Het Rendement op eigen vermogen ( 8.1% ) van EMBLA wordt als laag beschouwd.